{"title":"New Advances in the Treatment of Non-Small Cell Lung Cancer","authors":"S. Ramalingam","doi":"10.17925/OHR.2018.14.1.18","DOIUrl":null,"url":null,"abstract":"Support: No funding was received in the publication of this article. Q. Could you tell us a little about the PACIFIC trial in stage III nonsmall cell lung cancer (NSCLC)? The PACIFIC trial evaluated the role of durvalumab, a programmed death-ligand 1 (PD-L1) antibody, in patients with locally advanced, surgically unresectable stage III NSCLC. Following completion of chemotherapy and radiation, patients were randomized to receive one year of durvalumab or placebo. There was a significant improvement in progression-free survival (PFS) with durvalumab, with a hazard ratio of 0.52. The survival data are awaited. The results of the PACIFIC study have defined a new role for immunotherapy in the treatment of NSCLC. Clinical benefit was seen regardless of PD-L1 expression status.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"14 1","pages":"18"},"PeriodicalIF":0.7000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral History Review","FirstCategoryId":"98","ListUrlMain":"https://doi.org/10.17925/OHR.2018.14.1.18","RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HISTORY","Score":null,"Total":0}
引用次数: 1
Abstract
Support: No funding was received in the publication of this article. Q. Could you tell us a little about the PACIFIC trial in stage III nonsmall cell lung cancer (NSCLC)? The PACIFIC trial evaluated the role of durvalumab, a programmed death-ligand 1 (PD-L1) antibody, in patients with locally advanced, surgically unresectable stage III NSCLC. Following completion of chemotherapy and radiation, patients were randomized to receive one year of durvalumab or placebo. There was a significant improvement in progression-free survival (PFS) with durvalumab, with a hazard ratio of 0.52. The survival data are awaited. The results of the PACIFIC study have defined a new role for immunotherapy in the treatment of NSCLC. Clinical benefit was seen regardless of PD-L1 expression status.
期刊介绍:
The Oral History Review, published by the Oral History Association, is the U.S. journal of record for the theory and practice of oral history and related fields. The journal’s primary mission is to explore the nature and significance of oral history and advance understanding of the field among scholars, educators, practitioners, and the general public. The Review publishes narrative and analytical articles and reviews, in print and multimedia formats, that present and use oral history in unique and significant ways and that contribute to the understanding of the nature of oral history and memory. It seeks previously unpublished works that demonstrate high-quality research and that offer new insight into oral history practice, methodology, theory, and pedagogy. Work published in the journal arises from many fields and disciplines, reflecting the interdisciplinary nature of oral history. While based in the U.S., the Review reflects the international scope of the field and encourages work from international authors and about international topics.